Back to "The corresponding HR was 0.77 (95% CI 0...."
Strong Support
correlational
Analysis v3
History

In adults with type 2 diabetes who start injectable diabetes medication, those using GLP-1 receptor agonists have a lower risk of having a heart attack or being hospitalized for heart failure...

66
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

GLP-1 drugs help the heart burn fuel more efficiently and calm down harmful swelling in blood vessels, making heart attacks and heart failure less likely. This happens even in people who haven’t had heart problems before, and it’s not just because their blood sugar improved.

Most probable mechanism

In Simple Terms

GLP-1 receptor agonists help the heart use energy more efficiently and reduce swelling in blood vessels, which lowers the risk of heart attacks and heart failure.

Causal chain
1

GLP-1 receptor activation enhances myocardial glucose uptake and fatty acid oxidation, improving cardiac energy efficiency under metabolic stress

Supported by evidence
which leads to
2

Reduced systemic inflammation decreases endothelial dysfunction and arterial plaque instability

Supported by evidence
which leads to
3

Lowered blood pressure and improved vascular compliance reduce cardiac workload and prevent fluid retention

Supported by evidence

Evidence from Studies

Supporting (1)

66

Community contributions welcome

66

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

Cohort Study
Human
2021 Nov 13

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

Score: 66
DOI: 10.1186/s12933-021-01414-3

Similar Assertions

Among adults with type 2 diabetes starting injectable treatment, those using GLP-1 receptor agonists had a lower risk of heart attack, stroke, or death over two years compared to those using basal insulin, based on statistical analysis of patient data.

66
0
96%

For adults with type 2 diabetes starting injectable treatment, GLP-1 receptor agonists are linked to a 44% lower risk of severe low blood sugar episodes compared to basal insulin over two years.

66
0
94%

Among adults with type 2 diabetes who start injectable treatment, those who begin a GLP-1 receptor agonist have a 41% lower risk of dying from any cause and a 41% lower risk of having a stroke over two years compared to those who start basal insulin, based on observed data adjusted for other health factors.

66
0
93%

In adults who are overweight or obese but do not have diabetes, medications that activate GLP-1 receptors lower the likelihood of heart attacks, strokes, and other serious heart-related events compared to a placebo.

39
0
84%

If you're an overweight or obese adult without diabetes, taking GLP-1 drugs like Ozempic might lower your chances of having a heart attack by about 27% compared to taking a fake pill.

65
0
84%